Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs CAR-BCMA T cell therapy CARsgen (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2019 According to CARsgen Media Release, based on the data from this study, the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) eligibility to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cells (CT053) for the treatment of relapsed or refractory multiple myeloma.
- 12 Sep 2019 Results of pooled analysis from three phase I studies were presented at the 17th International Myeloma Workshop 2019.
- 04 Dec 2018 According to CARsgen Media Release, data from this study were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History